![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Tag: Coronavirus information (COVID-19)
Clinical Trials
Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced at Vaxart’s key opinion...
News
South Africa restarts inoculation with J&J’s Covid-19 vaccine
South Africa has resumed inoculation of health care workers with Johnson & Johnson’s (J&J) single-dose Covid-19 vaccine after a pause of over two weeks...
Press Releases
Moderna Announces Emergency Use Listing Granted by the World Health Organization for its COVID-19 Vaccine
Moderna, Inc. , a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the World Health Organization (WHO) has issued Emergency Use...
News
UK to host global summit with CEPI to speed up new vaccine development in 2022
The UK will host a summit with the Coalition for Epidemic Preparedness Innovations (CEPI) - a leading scientific coalition - to raise funds to...
News
American Airlines Cargo doubles cold chain flights to meet vaccine and pharma demand
American Airlines Cargo has expanded its temperature-controlled shipping capabilities to the company’s entire mainline fleet, nearly doubling its customers’ cold chain flight options and...
News
Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that it has entered into an agreement with Sanofi for fill/finish...
Drug Research
Moderna Announces Additional Investments to Increase Global Supply for COVID-19 Vaccine to up to 3 Billion Doses in 2022
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced it is making new funding commitments to increase supply at its...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read